 |
|
  |
 |
|
|
| NASD
Notice to Members 04-08 - February 2004 Effective Date of Amendments to NASD Rule 3370 (Affirmative Determination Requirements) Extended to April 1, 2004 NASD is delaying the effective date of amendments to Rule 3370 (Prompt Receipt and Delivery of Securities—the "Affirmative Determination" Rule) approved by the SEC in November 2003, until April 1, 2004. The amendments expand the scope of the affirmative determination requirements to include orders received from broker/dealers that are not members of NASD (“non-member broker/dealers”). The effective date of the amendments originally was February 20, 2004. NASD understands that some members need to make significant technological changes to their systems to comply with the new requirements; therefore, NASD is extending the effective date to provide members with additional time to make such changes. Questions concerning this Notice may be directed to Gary L. Goldsholle, Associate General Counsel, Regulatory Policy and Oversight, NASD, at (202) 728-8104; or Patricia M. Albrecht, Assistant General Counsel, Regulatory Policy and Oversight, NASD, at (202) 728-8026. |
| Ouro-- This is good news for advr but its value will remain intrinsic its an asset until the drug is apporved It is not news that will compell the masses or large institutions to buy on the bell imo--for the longer term investor, and for advr -its an asset they MUST have and if the drug progresses the value of all the patents will be factored in I also think that as P2 results come out 118 could get lots of attention IF the results are positive The patent be ever more valuable IF a P3 is done and the results are Positive The patent will serve advr well as other companies begin to look at Product R U must put patents like this into perspective for both on a Business and Scientific basis Its going to take time As for the bid and the ask--I does NOT bother me TA people might say ADVR is in a Channel from .13-.16 who knows for sure I dont look at advr the way the chronic crowd does like rar and mind and now you with you bid/ask question Thanks Allen |
| Think
about it... BASHERS 1.ADVR"s Yonker's Plant getting ready 2.NEW CEO Ms Hawkins Experience/Talent and very worthy 3.THANK you Mr.Dicke& Son 12 million, Better Financing 4.CHINA patent Award Pending 5.TEST Result AIDS/CANCER.from KAPLAN HOSP. REVOLT ISRAEL 6.TOPICAL AVR118 test continued PH 2 7.ADVR is looking for EXPOSURE from the meeting in ITALY 9.ADVR OWNS AVR118 PATENT AND 9 OTHERS WITH 20 PENDING 10.VOLUME IS UP UP!!!!!MEGA DRUG WAITING TO HAPPEN 11.MILLIONS NEED AVR118 NOW!! 12.Reticulose /Product R /AVR118,.. around for over 60 yrs....NON-TOXIC gator (Voluntary Disclosure: Position- Long; LT Rating |
| people
compare advr to lrp lrp has: 4 drugs in pipeline 4 trials diferent phases going fast track status sales of 1 drug overseas cancer grant funding plenty of money done many conferences just got on the amex and with that pr it went up .14 and has gone down to where it was at before it goes from .74-.96 right now its at about .85 so with all that where do you think advr should be? were at .15 |
| NUMBER
OF POSTS ON ADVR BOARD MIND................6,941 RAR.................1,175 KEV..................3,211 JMRHO............1,474 DIA......................475 MBENG..............279 MOST INTERESTING GET A LIFE |
| Facts: 1. The company has a grotesque history of material misrepresentations. 2. They have 800M outstanding shares. 3. Even at a paltry .15PPS, the financial community does not think the market cap is low. 4. They have only 10 employees (no R/D staff). 5. The copmpetition in this arena is fierce. 6. It's odd that the company in 18 yrs has not been able to put together a real clinical study to prove efficacy. 7. More than likely they will have a reverse split if they find a partner, devaluing the existing common shares. Need I go on? |
| rar-yes
go on if there is more why do you think there would have to be a reverse split ? [this is a legit question] I am not going to disagree with the fact that there appears to be a checkered past Yes they are where they are now by way of a slow road to china but fact is there has been a lot of progress over the last 8 months and to me that is very important Competition is Stiff, but it will not be for 118 if it gets approved especailly with those important patents only time will tell A |
| "The
price is way better about 250% better than the 6-7 cents it was stuck at" Tell that to the poor folks who bought in at $0.28 thinking it was going to $0.50. Or even those who bought in at $0.18. Allen it's NOT the MMs holding this down, it is a losing case of disinterest by the scientific/financial community. Only a partner will make this thing fly; and only top notch results will make a partner interested. We've got quite while to wait. So leave off your stridency and relax. |
| Allan Just one indicator RSI look at dec and feb Both were sell signals at or below 50 this is a buy look back and see. there are other indicators you have heard me talk about volume. The macd is a little late but it will confirm a move educate yourself on 3-4 indicators and paper trade for a while untill you get the hang... this stock has never let me down the move is slow but predictable. good luck! ck http://stockcharts.com/def/servlet/SC.web?c=advr,uu[m,a]daclyyay[pb50!b200][vc60][iUb14!La12,26,9]&pref=G |
| Ouro--good
post and it deserves an answer Its not a financial concern about having too much advr or not getting it out as you said Its more of a reaction by me when the progress the company has made is mocked. It just bothers me knocking the efforts of the people who work at advr and it makes a mockery indirectly of their patients and others connected with the effort. Also-- the constant negativity in the face of progress seems sinful I also should say for the record that I am here to make a return on my investment I dont want to give the idea Im not Thanks Allen |
| Generally
if an entity is trying to run the price up some (or support it), they
will not just dump $150,000 to "support it" - they buy in
small increments at the ask. If I were to guess, I'd say this is NOT a single entity, but some kind of bookkeepings going on with MMs. Perhaps indeed it may be the MMs looking forward to the April 1st short deadline and cleaning up their books. If this is so, by the way, you can expect NO change in pricing on April 1st, as all of this would have been taken care of by then. And also, if it IS a single entity, somebody simply wants in for whatever reason - perhaps to sell at a higher price (few pennies). Or what about any of the ADVR people who have options, to be buying in at this level?? As for institutions owning a LOT of shares as Allen says, there is NO way an institution would risk its portfolio on such a ridiculously risky investment as this. |
| Could
someone with some Pharm investment Knowledge/Experience let me know if
ADVR could Run to $5.00 if the Right Partner is Found?????? TIA only experienced Phram investors respond...please gator |
| AVR118
(previously known as Product R) is not approved by the U.S. Food and
Drug Administration or any comparable agencies of any other countries.
There is no assurance that the Company will be able to secure the
financing necessary to continue and/or complete the clinical trials of
AVR118 or satisfy certain other conditions relating to clinical trials
including obtaining adequate insurance on terms acceptable to the
Company or that if completed, clinical trials performed outside the
United States will assist the Company in obtaining FDA or other
regulatory approval. (Voluntary Disclosure: Position- No Position) |
| ADVR
Granted a United States Patent for the Treatment of AIDS Wednesday February 25, 8:14 am ET YONKERS, N.Y., Feb. 25 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR - News) today announced that it was issued a United States patent (No. 6,696,422) for the treatment of HIV infections with AVR118 as a combination therapy with other HIV drugs. The Centers for Disease Control and Prevention (CDC) estimates that 850,000 to 950,000 United States residents are living with HIV infection, one-quarter of whom are unaware of their infection. Over 40,000 new patients are diagnosed with HIV infections each year in the United States -- about 70 percent among men and 30 percent among women. Of these newly infected people, half are younger than 25 years of age. "The issuance of this patent allows us to increase our intellectual property protection in an important therapeutic area," said Dr. Elma Hawkins, President and CEO of Advanced Viral Research Corp. "We previously announced that China granted the Company a similar patent for AVR118 in the treatment of HIV infections." ADVR's AVR118 represents a biopolymer that possesses novel immunomodulator activity. This peptide-nucleic acid, which to date has shown a very favorable safety profile, appears to stimulate the proinflammatory responses required to combat viral infections such as HIV and human papillomavirus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. AVR118 is in clinical trials in Israel for the treatment of cachexia (body wasting) in patients with AIDS. For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com. Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (previously known as Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. . The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise. |
| ADVR
patent! Somebody should do their research and read the fine print! ADV118 works on AIDS patients with wasting disease. That is why the patent was applied for! Do you really think this company would go after a patent if it did not work in preliminary studies? (read israel news releases). The only problem this company truely had was money. Not a product problem. Now they have both a working product and money! It can only get better from here and out! |
| Hi
Folks, Any feedback on this presentation yet? Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that its spokesperson James T. D'Olimpio M.D has been invited to attend and present at the 1st ISC International Conference on Cancer Therapeutics Molecular Targets, Pharmacology and Clinical Applications to be held in Florence, Italy, from February 19 - 21, 2004. |
| Rob Look at it this way people who want to sell sold, we are happy to have them leave! this is a nice pr any way you slice it. I have made 196% on my last buy where is the problem??? People expect 100% in a couple days now?? It has always been a trading stock... that does not mean it has no potential.. it just means while the company is building the price fluctuates from time to time.. Looking for dark senarios and preaching gloom and doom is a joke.. if you are not beeing paid real nice I wonder about your sanity! cecil |
| OT:
Hey Gator- Found this on another board, but I thought you would like the
read.....And, that it would keep you busy for a while.... IAG.....-kevtod By: wow264 21 Feb 2004, 05:52 PM EST Msg. 46966 of 47000 Jump to msg. # Friends, I will call this the timeline to financial terrorism. The timeline I am about to show you will define dates and times by which our US Securities Regulators and US Law Enforcement Officials began to realize the magnitude of a manipulation scheme that has, to date, never been resolved for reasons I will discuss at the end of this memo. Reasons that will identify why our Securities Regulators are now playing Russian Roulette with Human lives to protect big business revenues. The Financial Terrorism is perpetrated through illegal offshore stock manipulation using “Naked Shorting” and it has created massive issues in our US Financial Institutions as our Brokerage firms accepted these trades for commission revenues. Timeline: 1996 – 2000 Securities and Exchange Commission (SEC) and FBI investigate Pacific International in Canada and their links to US Organized Crime. Pacific International being the conduit to Organized Crime Money Laundering. (http://www.rgm.com/articles/cornucopiaofcrooks.html) 1999 – SEC has an open comment period on Short Selling and receives more than 2000 comment letters addressing the abuses of Naked Shorting. No actions or reforms came from those comment letters. September 2000 – SEC speaks in front of Congress to discuss Organized Crime infiltration into Securities Markets. They speak heavily about the Micro-Caps as the easiest to infiltrate. (http://www.sec.gov/news/testimony/ts142000.htm) September 2000 – National Association of Securities Dealers (NASD) meets with Congress to discuss Organized Crime in the Markets and also discusses the Micro-Caps as the easiest to infiltrate. The NASD being an SRO consisting of the member bodies of Wall Street. (http://www.nasdr.com/1420/goldsmith_04.asp) 2000 – 2001 Sedona Corp. Addresses the SEC over trading abuses and stock manipulation taking place on their Security. They are accusing Rhino Advisors of Stock manipulation. SEC begrudgingly initiates investigation. January 2001 NASD bars Fiero Brothers from Industry and fines them $1 Million for Stock Manipulation, Illegal Shorting, and Extortion. No reforms came from this action. (http://www.nasdr.com/news/pr2001/ne_section01_003.html) 2001 – Naked shorting campaign begins by Micro-cap companies to address the short selling abuses. Many going public over the abuses they see in their stocks trading patterns. Complaints begin to pour into SEC and NASD over Brokers failures to deliver shares in physical form and failure to settle trades. Lawsuits are initiated against brokers for settlement failures on short sales. October 2001 NASD submits a reform bill to SEC for approval to “Close a Loophole” in offshore shorting practices. Request changes to Affirmative Determination requirements to address non-member shorting abuses (Offshore shorting). No response from SEC, Loophole and abuses remained in place. 2002 – Naked shorting campaign heats up with more than 100 publicly traded companies going public with their problems. Many try to take action by moving to “Certificate Only” trading and to exit the Electronic Settlement System of the Depository Trust (DTC). June 2002 – Genemax (OTCBB:GMXX) is the first of 6 Companies that had successfully exited the DTC Trade settlement system for “Certificate Only” Trading. Shareholder failures in receiving Certificates was evidence of counterfeit shares manipulating the Markets. SEC and NASD failed to take any actions for correction. August 2002 – Operation Bermuda Short – Joint FBI Royal Canadian Mounted Police (RCMP) sting operation concludes with nearly 60 arrests of offshore bankers and brokers associated with stock manipulation. Sting Operation took 3 years to complete. The manipulation of our Markets continued while this sting was in play. (http://www.globeandmail.com/servlet/ArticleNews/business/RTGAM/20020818/818bcbc/Business/businessBN/breakingnews-business ) (http://www.globeandmail.com/servlet/ArticleNews/business/RTGAM/20020816/wxmain/Business/businessBN/breakingnews-business ) 2002 – Foreign press initiates coverage on the “Naked Shorting” Problem with evidence of US Regulators working with Canadian Regulators on ‘Loophole” used to manipulate our markets. Even with Coverage in place, no real emphasis on corrections are being made. Entire situation is being downplayed by all. ( http://www.rgm.com/articles/blamecanada.html ) ( http://www.rgm.com/articles/predatororprey.html) (http://www.rgm.com/articles/nakedreview.html) December 2002 – Paul Lemmon pleads guilty in Operation Bermuda Shorts. Given light sentence for disclosing mechanisms to fraud and names. No net actions to date have been taken by the FBI or our Securities regulators based on the evidence provided by Mr. Lemmon (http://www.rgm.com/articles/tk2.html ) January 2003 – DTC seeks support of SEC to stop all Companies from exiting the electronic trading system for “Certificate Only” trading practices. Evidence to date by those that did exit was a disclosure of the settlement failures within the DTC settlement process. It became better to cover up the problem than expose it at the present time. In June the SEC supported the DTC’s request to stop future exiting from the system. Cite “potential” of Counterfeit paper and lost paper as a rationale while accepting the electronic counterfeit shares to remain in place. (http://www.dtcc.com/PressRoom/2003/nakedshorts.html) (http://www.sec.gov/rules/sro/34-47978.htm) February 2003 – SEC fines Rhino Advisors $1 Million for stock manipulation and short selling abuses to Sedona Corp. Stock. What will later be learned is that the SEC had evidence in hand regarding the bribery of US and offshore brokers to manipulate this security. No actions against a broker has ever taken place. No attempts at restitution to shareholders taken and no demand for unsettled trades to be settled by brokerage firms. Sedona’s stock remains oversold/manipulated to this day. (http://www.sec.gov/news/press/2003-26.htm ) 2003 – More companies join in war against short sellers. Public opinion of SEC cover-up grows. Grass Roots organization seeks full congressional investigation into the SEC’s criminal liabilities in allowing continued stock manipulation. (www.investigatethesec.com) October 2003 – SEC proposed regulation SHO to address shorting issues including “Naked Shorting”. SEC admits in background to proposal that “naked shorting” and settlement failures exceed the entire float of a company. (http://www.sec.gov/rules/proposed/34-48709.htm ). Comments to this reform include a letter from the North American Securities Administrators Association (NASAA) identifying that small companies and investors have been victimized by the short selling abuses. (http://www.nasaa.org/nasaa/Files/File_Uploads/Short%20Sales%20Comment.37990-38287.pdf) October 2003 – Forbes article identifies “naked shorting” as “Wall Street’s Next Nightmare”. Coverage of issue remains sparse. (http://www.forbes.com/forbes/2003/1013/066.html) November 2003 – SEC approves 2001 request by NASD to close offshore short selling loophole. December 2003 – Department of Justice (DOJ) arrest Andreas Badian (Rhino Advisors) under criminal indictment for Stock manipulation. Thomas Badian fled country just prior to arrest. DOJ provided audio tapes by SEC with Badian bribing US Brokers to “Collapse” stock. Like the SEC (Feb. 2003) the DOJ leaves the Brokers untouched in the criminal actions. (http://www.rgm.com/articles/DJwire6.html) January 2004 – Senate Banking committee council member identifies that a joint SEC/NASD task force is looking into the “Naked Shorting” abuses including the investigation into specific companies. Still no public address of the issue to prevent further abuses from evolving. January 2004 – NASD notifies members of the new rule change that was approved in November of 2003. Rule change to plug ‘loophole” used to manipulate our sock markets. Time table for incorporation – February 20, 2004 nearly 2.5 years from the original proposal to close loophole. (http://www.nasdr.com/pdf-text/0403ntm.txt) February 18, 2004 – NASD pushed out proposed rule change to April 1, 2004. Members request extension to closing “loophole” because February date was too inconvenient for them. Stalls on bringing closure to manipulation and abuse. (http://www.nasdr.com/filings/rf04_31.asp) Some within SEC and elsewhere identify that this “Extension” is the first of what could be several extension. The rights of member “Convenience” is put above the rights of investor protection. NASD and SEC decided it is better to deal with the additional manipulation than to have the members slightly inconvenienced until they can get their systems ready. Ready for changes they saw coming in 2001 when the NASD made these proposals. Now that you have seen a timeline that is extraordinary if you think about it, understand this. The revenues generated by this abusive practice has been quoted as being tremendous. (http://globeinvestor.com/servlet/ArticleNews/story/GAM/20040216/RREG16/stocks/news?ba). It is because of the revenues that this creates from both sides of the borders that the SEC and NASD have been so willing to let it slide. The SEC has never fully accepted the values of the Micro-cap stocks and thus, contrary to their September 2000 Congressional Hearing, they have elected to ignore protecting these companies. Companies whose primary investors are middle to lower class retail investors and not the wealthy or institutional buyers. The timeline alone demonstrates that. Now, however, the pressure is on and now the SEC is trying to protect the Wall Street institutions and Wall Street settlement systems integrity. To do so, they must continue to use these investors and these companies as the pawns. This decision brings them into criminal liabilities should they continue this practice. At the present time, our brokerage firms sit upside down on their books with the micro-cap positions they hold. Their shareholders combined have an example of 100 Million shares in micro cap positions. At the DTC Clearing House however, the DTC has only 5 Million in settled positions for that firm. That one firm is short a combined 95 Million shares and this is only 1 firm. Every firm is situated with a similar problem as the micro-caps have collectively been oversold by multiples of the registered shares. This is the problem the SC and member firms are trying to hide because, if these firms cannot back bill the original seller (Organized Crime in many cases) they then would be responsible for the buy-in of these positions. A solution that is not in the best interest of the member firms but is the best and most immediate restitution to the investors who have been defrauded. Ultimately it is about Money and who can lobby our congress and regulators best to acquire it. Finally, why the SEC is playing Russian Roulette with the lives of US people. There have been 4 people I am aware of that have had their lives threatened for fighting this abuse. To correct this problem will cost players (Organized Crime, Wall Street, etc…) some hundreds of billions to trillions in buy-in restitutions across the hundreds to thousands of abused companies. That loss in monies certainly can make some people angry and certainly groups known for their less than ethical manners in dealing with such situations. The SEC and DOJ are fully aware of this and the players involved and yet they continue to stall. They continue to allow further manipulations to happen and to let the situation continue to grow. They have no out that protects our Wall Street firms and thus they are willing to risk an actual event to happen in the mean time. An event that if it did happen would put our Country into complete turmoil if exposed. The gamble is to which comes first – Correction or Death? For those of you who have made it this far through the package I want to thank you. This has been long and detailed but it must be to show the proper trail of events that highlights a travesty of justice being perpetrated on the retail investor and Micro-cap stocks they invest in. In reality, this is the abridged version of a tale much more detailed and much more alarming that has consumed the lives of many for years. We have lived under this financial terrorism for years with no means of getting back out clean. Companies have gone bankrupt in the process and the US consumed those workers into our unemployment figures. We simply want it to end and we simply want restitution for the crimes committed upon us by Wall Street and the Wall Street Regulators. |
| Allan The only problem I have is a few new investors might look at all the noise and not fully see this company for what it is. I believe it is a great little company with a lot of potential. The team of professionals that are involved with this company are second to none (IMO) I have ten years untill I retire I want a million shares preferably without adding any more personal money! At that time I will have a million nothings or I will have a million shares of a fantastic biotec company that has developed the drug that changed the world! 10%of my investing net worth is riding on that outcome! I just get a laugh out of all the bashers who talk like every stock chart is a straight line drawn with a ruler. The one comfort I take I believe those that would benefit from a lower stock price are running scared. One decent day and they start speaking about the negatives! I look forward to 60-70 million crossing the tape at the ask! cecil |
| Cecil
says...."The only problem I have is a few new investors might look
at all the noise and not fully see this company for what it is." What NOISE???? Is Cecil referring to the noise on here? But, then again, Cecil is supposed to be "the" TA expert around here and I hardly think the "noise" is going to influence their collective thinking?....LOL. Psycho-babble, again and again!!! Someone pass Cecil a grape! TIA |
|
||||||
|
||||||||||||||||
| http://old.edgarpro.com/edgar_conv_html/2004/02/25/0000950144-04-001689.html#FIS_TOP_OF_DOCUMENT |
| "Currently,
we are determining whether to proceed with Phase 2 clinical trials of
AVR118 as a topical treatment for genital warts caused by HPV
infection." |
| From
the Prospectus.... "We are considering submitting an IND application to the FDA for the systemic use of AVR118 in clinical trials for the treatment of cachexia in AIDS patients in the US." I believe that's the first time I've seen this consideration in writing from ADVR? |
| ADVR
Granted a United States Patent for the Treatment of AIDS YONKERS, N.Y., Feb. 25 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) today announced that it was issued a United States patent (No. 6,696,422) for the treatment of HIV infections with AVR118 as a combination therapy with other HIV drugs. The Centers for Disease Control and Prevention (CDC) estimates that 850,000 to 950,000 United States residents are living with HIV infection, one-quarter of whom are unaware of their infection. Over 40,000 new patients are diagnosed with HIV infections each year in the United States -- about 70 percent among men and 30 percent among women. Of these newly infected people, half are younger than 25 years of age. "The issuance of this patent allows us to increase our intellectual property protection in an important therapeutic area," said Dr. Elma Hawkins, President and CEO of Advanced Viral Research Corp. "We previously announced that China granted the Company a similar patent for AVR118 in the treatment of HIV infections." ADVR's AVR118 represents a biopolymer that possesses novel immunomodulator activity. This peptide-nucleic acid, which to date has shown a very favorable safety profile, appears to stimulate the proinflammatory responses required to combat viral infections such as HIV and human papillomavirus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. AVR118 is in clinical trials in Israel for the treatment of cachexia (body wasting) in patients with AIDS. For further information regarding Advanced Viral Research Corp., please visit our website at http://www.adviral.com. Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (previously known as Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials performed outside the United States will assist the Company in obtaining FDA or other regulatory approval. . The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise. Contact: Ronnie Welch or Kelly Cinelli CWR & Partners 508/222-4802 SOURCE Advanced Viral Research Corp. Web site: http://www.adviral.com Company News On-Call: http://www.prnewswire.com/comp/903002.html CONTACT: Ronnie Welch or Kelly Cinelli, both of CWR & Partners,for Advanced Viral Research Corp., +1-508-222-4802 |
| ADVR's
AVR118 Granted a Patent in China for the Treatment of AIDS E-mail or Print this story 20 November 2003, 09:22am ET Large Potential Market as HIV Infection Continues Alarming Spread YONKERS, N.Y., Nov. 20 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (BB:ADVR) today announced that China has recently granted the Company a patent for the treatment of AIDS patients with AVR118 (formerly known as Product R). The claims in the patent awarded by China cover the administration of AVR118 in combination with other anti-HIV drugs. As previously reported, preliminary results from an Israeli clinical trial indicate that AVR118, a novel immunomodulator, may improve the quality of life of the patient, including increasing appetite, weight gain or stability and activities of daily living. AVR118 is also believed to be useful in enhancing the therapeutic effectiveness of the HAART drugs, as well as serving to mitigate the toxicity of HAART drugs. The United Nations currently estimates that there are 1.5 million HIV carriers in China. New HIV infections in China have been increasing annually by about 30%. Chinese officials and the United Nations have warned that 10 million people could be infected by 2020. "A recent United Nations Report on China found that the world is 'witnessing the unfolding of an AIDS epidemic of proportions beyond belief'," said Eli Wilner, Chairman of the Board of ADVR. "The report went on to note that China is on the verge of a catastrophe that could result in unimaginable suffering, economic loss and social devastation." "This patent not only further protects ADVR's intellectual property in a potentially large market, but also serves as an additional opportunity for us to broaden the awareness of what ADVR is attempting to accomplish in this therapeutic category," noted James T. D'Olimpio M.D. "The announcement of this patent can assist us in educating the world's researchers about ways to combat AIDS." Dr. D'Olimpio is a leading expert in oncology research and treatment who has focused on the areas of symptom control, palliative care, and cancer cachexia. Dr. D'Olimpio serves as a consultant to ADVR helping the Company to communicate the clinical results of AVR118 and speaking on issues related cachexia. He also serves on the Company's Scientific Advisory Board. ADVR recently announced the preliminary results of an Israeli clinical trial from the first fifteen cachectic (body wasting) AIDS patients treated with the novel immunomodulator AVR118. The results midway in this trial, first publicly announced on November 10, 2003, showed improvement in appetite, weight gain or stability, and enhanced quality of life in all patients. None of the 15 patients reported any significant side effects from AVR118 therapy. Mentioned Last Change ADVR 0.169 0.02dollars or (13.42%) "The enhancement of quality of life and the increase in activities of daily living observed in cachectic AIDS patients treated with AVR118 in the Phase I/II clinical trial in Israel carries the promise of returning AIDS patients to productive activity and relieve the economic burden imposed by this disease on the individual and society. If ultimately proven in further clinical trials, the value of AVR118 therapy in populations suffering with AIDS may be especially important in third world countries that are experiencing explosive growth, such as China," stated Shalom Z. Hirschman, M.D., Chief Scientist at ADVR and author of the patent. ADVR's AVR118 represents a biopolymer chemistry that possesses novel immunomodulator activity. This peptide-nucleic acid, which to date has shown no indication of human toxicity, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papilloma virus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. Therefore, AVR118 has been termed a "switch-type" immunomodulator. AVR118 is in clinical trials in Israel for the treatment of cachexia (body wasting) in patients with AIDS. For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com . Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise. Contact: Eli Wilner 914-376-7383 SOURCE Advanced Viral Research Corp. -0- 11/20/2003 /CONTACT: Eli Wilner of Advanced Viral Research Corp., +1-914-376-7383/ /Company News On-Call: http://www.prnewswire.com/comp/903002.html/ /Web site: http://www.adviral.com / (ADVR) CO: Advanced Viral Research Corp. ST: New York IN: HEA OTC MTC BIO SU: LK |
| Allen I go back a ways on this company.. I bought shares at .60 I have bought a lot more at .06 all for the same reason. This company has tremendous promise. My son who traded stock as a 16 years old is in his fourth year university paid for by his own efforts. He has not traded for two years and is still long this stock! My impatience with progress has never blinded me to the potential. At this time I am reluctant to part with any shares even for tripple and quadruple the prices I have paid. The reason for that is quite simple.. I believe within a year we will be partenered, fastracked, bought out or all of the above. No need to get caught napping chasing a few thousands with the potential for a million already in my accounts. ck (Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy) |
| Fox,
Reading the board today raised a few questions in my mind and I would
like you to help me if willing. I think by now most people know that my
life has been dedicated to helping those suffering with illness or
trauma. I stumbled accross this company (ADVR) a few years ago shortly
after deciding to try the stock market in order to give my family a
financial reward. I have informed any one willing to read my posts that
this drug will set multiple records, if there is such a thing in
healthcare in regards to the number of prescriptions written worldwide
for one drug that is indicated in at least eleven diseases by my last
count. Today there were a few posts that talked about people making a quick buck or two by selling and buying this stock. With the release of this drug being at least 2-3 years away how can the powers in the stock market allow this buying and selling of millions of shares without a company being able to sell a product and turn a profit for itself? I thought the market was about investing in a company that you beleive has a product or service to sell to others that will make it able to prosper as a business. This company has many questions to be answered before it can prosper, but all indications thus far tell me that their product will do just that. I know that the business of introducing new treatments to the suffering people of the world is a long process, but I thought investing in this kind of company means you trust in the research and are willing to ride it out. If the company depends on our dollars to continue it's forward push doesn't this type of buying and selling hurt ADVR's progress? Why would anyone investing in a health product producing company do anything to slow down it's progress, especially when there are many people suffering and waiting to benefit from this drug? Thanks, Mike |
| For
years ADVR misled its investors. For years ADVR itself has been selling
its own shares to pay its bills by way of dilution. For years no one
bought ADVR shares and there were huge lulls in activity. For YEARS
before Mind bought his 5,000 shares with Rarboston this penny sat all
day with virtually "picture still" quality volume + on one
press release - "THE BARBADOS STUDY". The fact that investors
buy a chunk of shares and sit on them is absolutely fine and acceptable.
Conversely -the small trades by investors like myself intraday # 1
create a market when duplicated by the efforts of many (I am assuming
here), and number #2 keeps the company alive. Has no impact to the
downside on this company what so ever. What does have impact is the
constant shorting, dilutive financing, lack on communications, lack of
conference calls etc by ADVR itselfffffff. Do you really think 2,500
investors are all trading intraday? More importantly what percentage of
them do you think do--- more like 5% if that? How's 10% NO impact there
even. I would put more pressure on CORNELL, Lack of Hirschman's
interests all of these years to take a position in his own company
as a risky investment. ADVR had many chances to do as successful
comapnys do ie; IPVO P VERGES/CEO FOUNDER Strides are being made with ADVR. WE are back to square one. Patents reissued, studies restudied, US trials agian refocused, refinaced, and good management like ELI WIlner (COB), and CEO . (Good luck 2 u as well) . My point is that all of this was at the expense of the share holders, and not the fault of my family nor yours. These guys like Rarboston and Mind complain all day of ADVR and its Management-I do not. They do not support this company nor their investment objectives. One would assume that they are the "Day" traders"/ AHA but they are not smart enough. lol IF we are speaking of millions of shares per trade on the day traders side we have a problem. Not in the quantities of the day to day traders. Market makers of today could not support millions of shares per trade on a day trade without volume so it is pointless to entertain my making such trades for this explanation here. IF the volume would support big trades then even those would help this company long term (creating a market) as in a day trade imhe. If traders short out a company to rebuy at a later date in massive dillutive efforts then we have a problem, but by then the SEC is well into the mix. UHUOO I might have given Mindless another thing to look into. I am a small time intraday trader only. cya rob |
| trade..
not advr, BILL BREGMANN wasted years got the fda and barrons pizzed and
did research with doctors from k-mart. were now doing what should of
been done almost 20 years ago. probably around 16 years ago i called
bozo bill during a quiet time (no news) and asked how advr was doing and
he said we got all are fingers in the pie. i get the feeling the report
bozo bill sent back then to the fda and that was the opening statement,
and there still laughing today, i got a ton of shares on the side and day trade at times with i call play shares. advr is going in the right direction now good luck |
| ejagacki: You have said here in a few posts that you are taking the company's drug for a medical condition. I'm just curious about certain things: 1. Is the drug you're taking labeled AVR118, Product R or Reticulose? Is it the Yonkers-made or Bahamas-made product according to the label? 2. How long have you been taking it? Do you take it by injection or sublingually? Have you tried both routes? 3. Do you obtain the drug through Canada, or how? Where do you get a prescription for it if it not yet an FDA-approved drug product? Does the company have a compassionate use protocol filed with the FDA to allow the product's use as an investigational drug outside of FDA-approved clinical trials? |
| Buckaroo: 1. Ampules are labelled Reticulose - AVR Ltd, Freeport 2. Approx 1 yr - strictly sub cutaneous injection (as far as I'm concerned, I know it works for me that way. While sublingually might work, I feel like I'd rather stick with what I KNOW works for me. 3. I get it through AVR Canada as an unapproved drug - with a Doctor's note agreeing that he will monintor my progress. PS - In answer to some UNASKED questions, it comes in boxes of 25 ampules for $200 ($8 per ampule). Each ampule is 2ml. and I take 1 ml per day. One can acquire a maximum of 3 boxes at a time. Hope this helps... |
| In
February 2004, we engaged Elma S. Hawkins, Ph.D. to be our President and
Chief Executive Officer on a full time basis. Pursuant to the employment
agreement dated February 10, 2004, the term of Dr. Hawkins’ employment
commenced on February 16, 2004 and continues for a term of two years
unless terminated earlier as provided in the agreement. Pursuant to the
agreement, Dr. Hawkins receives a base salary of $350,000 per year, and
is eligible to receive an annual cash bonus of up to 50% of her then
base salary based on certain performance objectives in the sole
discretion of the Board of Directors. In addition, we agreed to pay Dr.
Hawkins a signing bonus of $50,000. Pursuant to the agreement, Dr.
Hawkins received an option to purchase 40 million shares of our common
stock which options become exercisable monthly over for five years so
long as she is employed by Advanced Viral at exercise prices ranging
from $0.12 to $0.160. |
| A
third test was done by the Weizmann Institute to assess the efficacy of
oral AVR 118 in mice with an induced immune skin reaction. AVR 118 did not inhibit the appearance of this immune skin reaction. ******************************************************** |
| OT:
Raboston You sound pretty short term to me 4 tenths of a penny either way does not excite me.. When I was calling a screaming buy at .06 I was already loaded to the gills as was the group.. My latest discussions with barry as to .15 holding is based on a technical point that is a little past some.. Barry disagrees I can respect that. When trying to accumulate more stock the idea is only to sell the amount of the original purchass and wait for a dip and hit it again. If you want to make money you sell the whole amount and wait for the dip to ride it up again. Now some believe if I were a true long I would have made my original purchass at .60 and held on never doing anything except bitc# and moan about my investment. On the other hand I decided to do something about it and devise a way to reduce my average cost and accumulate shares in a company I believe in.. If that makes me bad so be it! going up or down is relative... if you are not going in a direction to make money wait untill you do! The stock moves, only an idiot would not take advantage of that fact! you wonder how I make money here? some would ask the same of you! If you are not paid as a basher why would you spend the time??? There is no sweat to make a couple grand most days trading 10 to 15 thousand dollar account.. Live large understand the herding mentality of humans! the rest is easy! cecil |
| Kevtod
- You have pointed out a 10 month process to prepare and submit an INDA
for systemic. The next 10-K due by March 31st and the next 10-Q due by
May 15th will reveal the amount expensed to Oxford in Q4/2003 and
Q1/2004. This will indicate whether the 10 month clock started last
October or not. If Oxford began the process of preparing the INDA for systemic HIV last October, we should expect an INDA submitted sometime in Q3/2004, which if approved would come 30 to 60 days after submission...that is by the end of the year. And, it is my understanding that ADVR has been in the process of preparing the systemic INDA for HIV for some time now. The final results from Israel will be included. The 10-K and 10-Q coming in the next few months should shed light on how far along ADVR is in the process and whether or not ADVR will submit a systemic INDA by the end of the year. |
| shag-
Sounds good to me.....Then we will see if Madam Hawkins can shake up 100
million or so to really get the ball rolling..... GOOOOOOO ADVR !!! IAG......-kevtod |
| ADVR's
AVR118 Granted a Patent in China for the Treatment of AIDS E-mail or Print this story 20 November 2003, 09:22am ET Large Potential Market as HIV Infection Continues Alarming Spread YONKERS, N.Y., Nov. 20 /PRNewswire-FirstCall/ -- Advanced Viral Research Corp. (BB:ADVR) today announced that China has recently granted the Company a patent for the treatment of AIDS patients with AVR118 (formerly known as Product R). The claims in the patent awarded by China cover the administration of AVR118 in combination with other anti-HIV drugs. As previously reported, preliminary results from an Israeli clinical trial indicate that AVR118, a novel immunomodulator, may improve the quality of life of the patient, including increasing appetite, weight gain or stability and activities of daily living. AVR118 is also believed to be useful in enhancing the therapeutic effectiveness of the HAART drugs, as well as serving to mitigate the toxicity of HAART drugs. The United Nations currently estimates that there are 1.5 million HIV carriers in China. New HIV infections in China have been increasing annually by about 30%. Chinese officials and the United Nations have warned that 10 million people could be infected by 2020. "A recent United Nations Report on China found that the world is 'witnessing the unfolding of an AIDS epidemic of proportions beyond belief'," said Eli Wilner, Chairman of the Board of ADVR. "The report went on to note that China is on the verge of a catastrophe that could result in unimaginable suffering, economic loss and social devastation." "This patent not only further protects ADVR's intellectual property in a potentially large market, but also serves as an additional opportunity for us to broaden the awareness of what ADVR is attempting to accomplish in this therapeutic category," noted James T. D'Olimpio M.D. "The announcement of this patent can assist us in educating the world's researchers about ways to combat AIDS." Dr. D'Olimpio is a leading expert in oncology research and treatment who has focused on the areas of symptom control, palliative care, and cancer cachexia. Dr. D'Olimpio serves as a consultant to ADVR helping the Company to communicate the clinical results of AVR118 and speaking on issues related cachexia. He also serves on the Company's Scientific Advisory Board. ADVR recently announced the preliminary results of an Israeli clinical trial from the first fifteen cachectic (body wasting) AIDS patients treated with the novel immunomodulator AVR118. The results midway in this trial, first publicly announced on November 10, 2003, showed improvement in appetite, weight gain or stability, and enhanced quality of life in all patients. None of the 15 patients reported any significant side effects from AVR118 therapy. Mentioned Last Change ADVR 0.169 0.02dollars or (13.42%) "The enhancement of quality of life and the increase in activities of daily living observed in cachectic AIDS patients treated with AVR118 in the Phase I/II clinical trial in Israel carries the promise of returning AIDS patients to productive activity and relieve the economic burden imposed by this disease on the individual and society. If ultimately proven in further clinical trials, the value of AVR118 therapy in populations suffering with AIDS may be especially important in third world countries that are experiencing explosive growth, such as China," stated Shalom Z. Hirschman, M.D., Chief Scientist at ADVR and author of the patent. ADVR's AVR118 represents a biopolymer chemistry that possesses novel immunomodulator activity. This peptide-nucleic acid, which to date has shown no indication of human toxicity, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papilloma virus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. Therefore, AVR118 has been termed a "switch-type" immunomodulator. AVR118 is in clinical trials in Israel for the treatment of cachexia (body wasting) in patients with AIDS. For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com . Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for viral and other diseases. Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise. Contact: Eli Wilner 914-376-7383 SOURCE Advanced Viral Research Corp. -0- 11/20/2003 /CONTACT: Eli Wilner of Advanced Viral Research Corp., +1-914-376-7383/ /Company News On-Call: http://www.prnewswire.com/comp/903002.html/ /Web site: |
| Orphan
Drug Regulations http://www.fda.gov/orphan/odreg.htm (Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy) |
| Orphan
Drug Regulations http://www.fda.gov/orphan/odreg.htm (Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy) |
| THE
VICTORY GOES TO FOXY. The Loop Group could not handle her not one on one or as a group Now you can deal with me. Allen |
| OT:
To MM's who going short on advr ...................../´¯/) ...................,/¯../ ................../..../ ............./´¯/'...'/´¯¯`•¸ ........../'/.../..../......./¨¯\ ........('(...´...´.... ¯~/'...') .........\.................'...../ ..........''...\.......... _.•´ ............\..............( ..............\.............\.. |
| Barry
for the sake of discussion let us look at the post I made to you when
the stock was trading at .08 as you know it closed at .28 on dec 1 after
the dec high it got back to .12 briefly I was buying at .15 Hey! I am
not perfect! A three bagger on free advice!!! I am not sure what you should expect for FREE! Cecil 26 Nov 2003, 04:26 PM EST Msg. 127341 of 140685 (This msg. is a reply to 127333 by mind31.) Jump to msg. # Barry see that? Almost a carbon copy of the interday charts we have seen for a few days! a little selling untill mid day and the buyers come in. The increasing volume is the most interesting part. I have not been this excited since I held this stock above a dollar. If this is a pump on minor news I will be amazed... Somebody is gathering a lot of shares we may get interesting real soon.. good luck to us all. ck |
| met--imo
ADVR needs data on a larger no. of patients i feel the same way you do about their potential and what this might mean. I believe if the data proves out in larger numbers the price will follow. that may just take a long time though.Other events including the Isreal trial results can help move the price quite a bit and a expeditied status trial could help more. Nothing will rocket the price though like a positve P3 or fastrack that when the data is reported and reflects several hundred patients is very positive. Prepare to wait a long time. Allen |
| summer
would be nice. I would not expect too much on the price like a run to 5 bucks or something I just think that the results could be super encouraging but NOT enough to prove itself in the medical world must have a large trial for maybe two yrs if it takes that long. it has to be done right IMO Allen |
| Allan Quick short explanitation... I am LONG real long for a person with my income and means. I have traded this stock mostly for the increase in shares that trading has allowed me. I hold a core position that are basically free I never trade them! Example If I buy 100,000 at .07 and sell half at .14 50,000 are free. The next move could be another 100,000 at .15 and sell 66,000 at .20 another 33,00 free shares and so on and so on.... Nothing fancy but it works! ck |
